# **Practitioner's Docket No. MBIO99-057CP2RCEM**

MAR 1 4 2007 & TRADEMA

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In reapplication of:

Samantha J. Busfield and Jean-Luc M.G. Villeval

plication No.:

09/503,387

Group No.:

1644

February 14, 2000

Examiner:

Huynh, Phuong N.

For:

GLYCOPROTEIN VI AND USES THEREOF

Confirmation No. 6531

Mail Stop Issue Fee **Commissioner for Patents** P.O. Box 1450 Alexandria, VA 22313-1450

#### **TRANSMITTAL**

- 1. Transmitted herewith for this application is/are:
  - This Transmittal (2 pages); a.
  - b. Transmittal of Payment of Issue Fee (2 pages – in duplicate);
  - Part B Fees Transmittal (1 page in duplicate); and c.
  - Return Postcard. d.

#### **STATUS**

2. Applicant is other than a small entity.

#### CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\*

I hereby certify that, on the date shown below, this correspondence is being:

## **MAILING**

× deposited with the United States Postal Service in an envelope addressed to Mail Stop Issue Fee, Commissioner for Patents, Washington, D.C. 20231.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10\*

X with sufficient postage as first class mail. as "Express Mail Post Office to Address"

Mailing Label No.

**TRANSMISSION** 

transmitted by facsimile to the Patent and Trademark Office.

**Signature** 

Date: March 12, 2007

Sean Hunziker

(type or print name of person certifying)

<sup>\*</sup>WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

# Practitioner's Docket No. MBIO99-057CP2RCEM

### **FEE DEFICIENCY**

3. Papers contained herein authorize payment of Issue Fees. It is believed no additional fees are required, however, if any additional extension and/or fee is required, charge Account No. 501668. If any additional fee for claims is required, charge Account No. 501668.

March 12, 2007

MILLENNJUM PHARMACEUTICALS, INC.

Mario Cloutier

Registration No. 57,225

40 Landsdowne Street

Cambridge, MA 02139

Telephone – (617) 577-3522

Facsimile – (617) 551-8820

PART B - FEE(S) TRANSMITTAL toplete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE Commissioner for Patents P.O. Box 1450 MAR 1 4 2007 Alexandria, Virginia 22313-1450 or <u>Fax</u> (571)-273-2885 INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks I through 5 should be completed where appropriate All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless correspondence or directed otherwise in Block I, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address) Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission. 30405 7590 01/26/2007 Certificate of Mailing or Transmission MILLENNIUM PHARMACEUTICALS, INC. I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below. 40 Landsdowne Street CAMBRIDGE, MA 02139 03/14/2007 MWDLDGE2 00000041 501668 09503387 Hunziker (Depositor's name 01 FC:1501 1400.00 DA 02 FC:8001 9.00 DA (Signature (Date APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 09/503,387 02/14/2000 Samantha J. Busfield MBIO99-057CP2RCEM 6531 TITLE OF INVENTION: GLYCOPROTEIN VI AND USES THEREOF APPLN. TYPE **SMALL ENTITY** ISSUE FEE DUE PUBLICATION FEE DUE PREV. PAID ISSUE FEE TOTAL FEE(S) DUE DATE DUE nonprovisional NO \$1400 \$0 \$0 \$1400 04/26/2007 **EXAMINER ART UNIT CLASS-SUBCLASS** HUYNH, PHUONG N 1644 435-069100 1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363). 2. For printing on the patent front page, list (1) the names of up to 3 registered patent attorneys or agents OR, alternatively, Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. Millennium Pharmaceuficals (2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required. 2 registered patent attorneys or agents. If no name is listed, no name will be printed. 3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment. (B) RESIDENCE: (CITY and STATE OR COUNTRY) Millennium Pharmaceuticals, Inc. Cambridge, MA Please check the appropriate assignee category or categories (will not be printed on the patent): ☐ Individual ☐ Corporation or other private group entity ☐ Government 4a. The following fee(s) are submitted: 4b. Payment of Fee(s): (Please first reapply any previously paid issue fee shown above) Issue Fee A check is enclosed. Publication Fee (No small entity discount permitted) Payment by credit card. Form PTO-2038 is attached. Advance Order - # of Copies The Director is hereby authorized to charge the required fee(s), any deficiency, or credit any overpayment, to Deposit Account Number 501668 (enclose an extra copy of this form). 5. Change in Entity Status (from status indicated above) a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the Upited States Patent and Trademark Office. Authorized Signature Date March 12, 2007 Typed or printed name Mario Cloutier 57,225 Registration No.

This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.